-
公开(公告)号:US20090221671A1
公开(公告)日:2009-09-03
申请号:US11915124
申请日:2006-05-24
申请人: Sanjay Pandey , Robert McKay , Sanjay Bhanot , Xing-Xian Yu
发明人: Sanjay Pandey , Robert McKay , Sanjay Bhanot , Xing-Xian Yu
IPC分类号: A61K31/7088 , C07H21/00 , A61P3/10
CPC分类号: C12N15/1137 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12Y301/03048 , C12N2310/3525
摘要: Disclosed herein are compounds, compositions and methods for modulating the expression of LMW-PTPase in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, and hyperfattyacidemia. In some embodiments, the diabetes is type II diabetes by administration of antisense compounds targeted to LMW-PTPase.
摘要翻译: 本文公开了用于调节细胞,组织或动物中LMW-PTPase表达的化合物,组合物和方法。 还提供了目标验证的方法。 还提供了所公开的化合物和组合物在制备用于治疗疾病和病症的药物中的用途。 还提供了用于预防,改善和/或治疗糖尿病,胰岛素抵抗,胰岛素缺乏,高胆固醇血症,高血糖,血脂异常,高脂血症,高甘油三酯血症和高脂肪酸血症的方法。 在一些实施方案中,通过施用靶向LMW-PTPase的反义化合物,糖尿病是II型糖尿病。
-
公开(公告)号:US09045754B2
公开(公告)日:2015-06-02
申请号:US11745429
申请日:2007-05-07
申请人: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
发明人: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
IPC分类号: C12N15/113
CPC分类号: C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译: 本公开描述了短反义化合物,包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。 某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞,组织和动物中还原靶核酸和/或蛋白质。 因此,本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。 这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的,允许降低毒性和治疗成本。 此外,所述短反义化合物具有更大的口服给药潜力。
-
公开(公告)号:US20090306179A1
公开(公告)日:2009-12-10
申请号:US12299609
申请日:2007-05-07
申请人: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
发明人: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
IPC分类号: A61K31/7052 , C07H21/00 , C12N5/00 , A61P3/00
CPC分类号: C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译: 本公开描述了短反义化合物,包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。 某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞,组织和动物中还原靶核酸和/或蛋白质。 因此,本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。 这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的,允许降低毒性和治疗成本。 此外,所述短反义化合物具有更大的口服给药潜力。
-
公开(公告)号:US20090292006A1
公开(公告)日:2009-11-26
申请号:US12299605
申请日:2007-05-07
申请人: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
发明人: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
CPC分类号: C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译: 本公开描述了短反义化合物,包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。 某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞,组织和动物中还原靶核酸和/或蛋白质。 因此,本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。 这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的,允许降低毒性和治疗成本。 此外,所述短反义化合物具有更大的口服给药潜力。
-
公开(公告)号:US08853178B2
公开(公告)日:2014-10-07
申请号:US13177462
申请日:2011-07-06
申请人: Sanjay Bhanot , Lex M. Cowsert , Jacqueline R. Wyatt , Brett P. Monia , Madelline M. Butler , Robert McKay , Susan M. Freier , Kenneth W. Dobie
发明人: Sanjay Bhanot , Lex M. Cowsert , Jacqueline R. Wyatt , Brett P. Monia , Madelline M. Butler , Robert McKay , Susan M. Freier , Kenneth W. Dobie
IPC分类号: C12N15/113
CPC分类号: C12N15/113 , A61K38/00 , A61K48/00 , C12N15/1137 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12Y301/03048 , Y02P20/582 , C12N2310/3525
摘要: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
摘要翻译: 提供化合物,组合物和方法用于调节PTP1B的表达。 组合物包含靶向编码PTP1B的核酸的反义化合物,特别是反义寡核苷酸。 提供了使用这些化合物调节PTP1B表达和治疗与PTP1B表达相关的疾病的方法。
-
公开(公告)号:US08673871B2
公开(公告)日:2014-03-18
申请号:US12299764
申请日:2007-05-07
申请人: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
发明人: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
CPC分类号: C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译: 本公开描述了短反义化合物,包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。 某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞,组织和动物中还原靶核酸和/或蛋白质。 因此,本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。 这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的,允许降低毒性和治疗成本。 此外,所述短反义化合物具有更大的口服给药潜力。
-
公开(公告)号:US08586554B2
公开(公告)日:2013-11-19
申请号:US12299607
申请日:2007-05-07
申请人: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
发明人: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
IPC分类号: C12N15/11
CPC分类号: C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译: 本公开描述了短反义化合物,包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。 某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞,组织和动物中还原靶核酸和/或蛋白质。 因此,本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。 这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的,允许降低毒性和治疗成本。 此外,所述短反义化合物具有更大的口服给药潜力。
-
公开(公告)号:US08362232B2
公开(公告)日:2013-01-29
申请号:US12883049
申请日:2010-09-15
申请人: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
发明人: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
IPC分类号: C07H21/04
CPC分类号: C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译: 本公开描述了短反义化合物,包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。 某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞,组织和动物中还原靶核酸和/或蛋白质。 因此,本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。 这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的,允许降低毒性和治疗成本。 此外,所述短反义化合物具有更大的口服给药潜力。
-
公开(公告)号:US08299041B2
公开(公告)日:2012-10-30
申请号:US11910606
申请日:2006-04-10
IPC分类号: A61K48/00
CPC分类号: C12N15/1137 , A61K31/202 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/3521
摘要: Disclosed herein are compounds, compositions and methods for modulating the expression of ACC1 or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
摘要翻译: 本文公开了用于在细胞,组织或动物中调节ACC1或ACC2或两者的表达的化合物,组合物和方法。 还提供了所公开的化合物和组合物在制备用于治疗疾病和病症的药物中的用途。
-
公开(公告)号:US07897583B2
公开(公告)日:2011-03-01
申请号:US11915309
申请日:2006-05-24
申请人: Robert McKay , Ravi Jain , Kenneth W. Dobie , Sanjay K. Pandey , Sanjay Bhanot
发明人: Robert McKay , Ravi Jain , Kenneth W. Dobie , Sanjay K. Pandey , Sanjay Bhanot
CPC分类号: C12N15/1137 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12Y301/03048 , C12N2310/3525
摘要: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease by administration of antisense compounds targeted to PTPRU.
摘要翻译: 本文公开了用于调节细胞,组织或动物中PTPRU表达的化合物,组合物和方法。 还提供了主动目标段验证的方法。 还提供了所公开的化合物和组合物在制备用于治疗疾病和病症的药物中的用途。 还提供了用于预防,改善和/或治疗糖尿病,肥胖症,胰岛素抵抗,胰岛素缺乏,高胆固醇血症,高血糖症,高脂血症,高甘油三酯血症,高脂肪肝,肝脂肪变性,脂肪性肝炎,非酒精性脂肪性肝炎,代谢综合征,心血管疾病和 通过给予针对PTPRU的反义化合物的冠心病。
-
-
-
-
-
-
-
-
-